MosquitoMate receives first Vector Expedited Review Voucher (VERV) from the US Environmental Protection Agency
The MosquitoMate pesticide is innovative in multiple ways: it is a new and effective active ingredient and a novel delivery method. MosquitoMate makes and releases male mosquitoes that are infected with the Wolbachia bacterium. The approach does not use genetic modification and is listed as an organic product. "The male mosquitoes are 'self-delivering' and do not bite or transmit disease-causing pathogens," describes Dr.
MosquitoMate began working with the EPA years before the VERV was proposed. "We are thrilled that the WB1 male mosquitoes are being recognized by the EPA's new VERV program," exclaims Dobson. The WB1 male mosquito is effective against the Aedes aegypti mosquito (commonly known as the Yellow Fever mosquito), which occurs around the world and is responsible for transmission of dengue, Zika, chikungunya and yellow fever pathogens. This mosquito prefers to feed on people, and it is perfectly adapted to live and breed in the communities that humans create. One published study from
"The problem is growing," describes Dobson, "and the combination of climate change and increasing globalization of goods and human travel is making matters worse, both inside the
"The Ae. aegypti mosquito is an invasive species in the
The VERV program was championed by a consortium that includes Duke University's Global Health Institute and the Innovative Vector Control Consortium (IVCC) program.
Contact:
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/mosquitomate-receives-first-vector-expedited-review-voucher-verv-from-the-us-environmental-protection-agency-302325490.html
SOURCE MosquitoMate, Inc
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease
- O-RAN ALLIANCE Announces Its New Board of Directors for the Term 2024-2026
- Merit Medical Announces Preliminary Unaudited Revenue for the Year Ended December 31, 2024 and Plans to Announce Fourth Quarter and Year End 2024 Results and Issue Fiscal Year 2025 Guidance on Februar
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!